CompletedPhase 1NCT06684431

Study to Evaluate Safety and Immunogenicity of DNA Vaccine N-pVAX1 Against Crimean Congo Hemorrhagic Fever

Studying Crimean-Congo hemorrhagic fever

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Karolinska Institutet
Principal Investigator: Soo Aleman, MD, PhD
Karolinska University Hospital
Intervention: N-pVAX1(biological)
Enrollment: 15 enrolled
Eligibility: 18-60 years · All sexes
Timeline: 2024 – 2026

Study locations (1)

Phase I Unit, Karolinska University Hospital, Stockholm, Stockholm County, Sweden

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06684431 on ClinicalTrials.gov

Other trials for Crimean-Congo hemorrhagic fever

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE1NCT06799013
Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic Fever
HDT Bio

See all trials for Crimean-Congo hemorrhagic fever →

← Back to all trials